Trials / Completed
CompletedNCT00239928
Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration
Long-Term Study For Pegaptanib Sodium In Patients With Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration (Extension Study From A5751010)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 51 Years
- Healthy volunteers
- Not accepted
Summary
This study will examine the safety and efficacy of pegaptanib sodium in Japanese patients with wet-type age-related macular degeneration (AMD), who benefit further treatment and who want to continue the treatment after completion of the preceding study (A5751010).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pegaptanib sodium | 1 drop per dosed eye per protocol. |
Timeline
- Start date
- 2005-09-01
- Primary completion
- 2008-11-01
- Completion
- 2008-11-01
- First posted
- 2005-10-17
- Last updated
- 2011-05-12
- Results posted
- 2011-05-04
Locations
12 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00239928. Inclusion in this directory is not an endorsement.